Author

C. Beausejour

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 5 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:human· 6 Research Focus:cancer & tumor microenvironment· 5 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2

Frequent Co-Authors

C. Colas· 4 shared E. Haddad· 4 shared Y. Li· 4 shared B. Benabdallah· 3 shared D. Maggiorani· 3 shared G. Moquin-Beaudry· 3 shared J. V. Guimond· 3 shared S. McGraw· 2 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCell Biology

C. Colas

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Nuclear Location Bias of HCAR1 Drives Cancer Malignancy through Numerous Routes

M. A. M. Nezhady, G. Cagnone, E. Bajon, P. Chaudhari, M. Modaresinejad, P. Hardy, D. Maggiorani, C. Quiniou, J.-S. Joyal, C. Beausejour, S. Chemtob

This study identifies nuclear localization of HCAR1 as a driver of cancer malignancy through multiple mechanisms including nuclear signaling and transcriptomic regulation.

bioRxiv · Jul 25, 2022 · PreprintCell Biology

Clearance of defective muscle stem cells by senolytics reduces the expression of senescence-associated secretory phenotype and restores myogenesis in myotonic dystrophy type 1.

T. Conte, G. D. Bishop, Z. Orfi, I. Mokhtari, A. Deprez, M.-P. Roussel, I. Cote, O. Pellerito, D. Maggiorani, B. Benabdallah, S. Leclerc, L. Feulner, J. Mathieu, C. Gagnon, G. Andelfinger, , N. Dumont

This study identifies a senescent molecular signature in DM1 myogenic cells and shows that senolytics reduce SASP and restore myogenesis.

bioRxiv · Jun 22, 2022 · PreprintCell Biology

Autologous humanized mouse models of iPSC-derived tumors allow for the evaluation and modulation of cancer-immune cell interactions

G. Moquin-Beaudry, B. Benabdalah, D. Maggiorani, O. Le, Y. Li, C. Colas, C. Raggi, B. Ellezam, M. M'Callum, D. Dal Soglio, J. V. Guimond, M. Paganelli, E. Haddad, C. Beausejour

This paper develops autologous humanized mouse models of iPSC-derived tumors to study and modulate cancer-immune interactions, showing immune infiltration and response to PD-1 inhibition.

bioRxiv · Apr 2, 2021Cancer Biology

NK cells prevent the formation of teratomas derived from human induced pluripotent stem cells

B. Benabdallah, C. Deslauniers-Langevin, C. Colas, Y. Li, J. Guimond, E. Haddad, C. Beausejour

This study shows that NK cells prevent teratoma formation from hiPSCs in immune competent hosts, while autologous T cells can reject established teratomas.

bioRxiv · Jul 25, 2019Cell Biology

Immune tolerance of human induced pluripotent stem cell-derived myogenic progenitor cells in humanized mice

B. Benabdallah, C. Desaulniers-Langevin, M.-L. Goyer, C. Colas, C. Maltais, Y. Li, J. V. Guimond, J. P. Tremblay, E. Haddad, C. Beausejour

This study evaluates immune tolerance of hiPSC-derived myogenic progenitor cells in humanized mice, finding autologous cells are tolerated while allogeneic grafts are rejected, and NK cell transfer prevents teratoma formation.

bioRxiv · Jul 11, 2019 · PreprintCell Biology

The tumor immune response is not compromised by mesenchymal stromal cells in humanized mice

G. Moquin-Beaudry, C. Colas, Y. Li, R. Bazin, J. V. Guimond, E. Haddad, C. Beausejour

This study shows that human umbilical cord mesenchymal stromal cells do not affect tumor growth or immune rejection in humanized mice.

bioRxiv · Jul 11, 2019Cell Biology

Targeting MYC Overexpressing Leukemia with Cardiac Glycoside Proscillaridin Through Downregulation of Histone Acetyltransferases

E. M. Da Costa, G. Armaos, G. McInnes, A. Beaudry, G. Moquin-Beaudry, V. Bertrand-Lehouillier, M. Caron, C. Richer, P. St-Onge, J. Johnson, N. Krogan, Y. Sai, M. Downey, M. Rafei, M. Boileau, , N. J. M. Raynal

This study shows proscillaridin, a cardiac glycoside, selectively targets MYC overexpressing leukemia by downregulating histone acetyltransferases and inducing hematopoietic differentiation.

bioRxiv · Dec 11, 2018 · PreprintPharmacology & Toxicology